DataMeds acquires Helomics for $1.5M in stock and convertible note, expanding into cancer diagnostics

Wellgistics Health, Inc.

Paid 636,328 shares (~19.99% of MEDS outstanding) plus $1.363M 7% convertible note due Sept 2029; conversion at $1.00/share pending Nasdaq approval.
Helomics brings CLIA/CAP-certified lab, Predictive Oncology CRO, and $1.5M cash; no third-party debt or unpaid payables.
Expands DataMEDS beyond GLP-1 and Long COVID into $40B U.S. cancer diagnostic/treatment market.
Seller Axe Compute (AGPU) retains shareholder stake; agrees to 12-month transfer lock-up and 6-month vote-alignment with DataMeds board.
Deal closed Sept 11, 2026; Helomics becomes wholly owned subsidiary of DataMeds AI.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.